Skip to main content

Table 1 Demographic and clinicopathologic characteristics of the 111 unselected patients with endometrial cancer

From: Comparison of screening strategies for Lynch syndrome in patients with newly diagnosed endometrial cancer: a prospective cohort study in China

Characteristic

Total

Germline MMR gene mutation

IHC MMR protein

MSI

Absence

Presence

p value

Intact

Deficient

p value

Negative

Positive

p value

Total (cases)

111

105

6

 

74

28

 

71

12

 

Age (years; median [range])

 

56.00 (31–82)

54.00 (48–57)

0.440

56.50 (32–82)

53.50 (31–73)

0.102

57.00 (32–82)

55.00 (40–73)

0.658

Gravidity [median (range)]

 

2 (0–7)

2 (0–5)

0.374

2 (0–5)

2 (0–7)

0.437

2 (0–7)

2 (0–5)

0.020

Parity (median, range)

 

1 (0–4)

1 (0–2)

0.779

1 (0–4)

1 (0–2)

0.498

1 (0–4)

1 (0–3)

0.189

BMI (kg/m2; median [range])

 

24.98 (19–32)

21.60 (19–23)

0.010

25.66 (19–32)

24.27 (20–32)

0.622

24.98 (19–32)

23.87 (19–31)

0.343

Involvement of the lower uterine segment [cases (%)]

27

24 (22.9)

3 (50.0)

0.132

17 (23.0)

9 (32.1)

0.343

14 (19.7)

4 (33.3)

0.290

Type of EC [cases (%)]

   

0.189

  

0.983

  

0.937

 Type I

87

81 (77.1)

6 (100.0)

 

58 (78.4)

22 (78.6)

 

54 (76.1)

9 (75.0)

 

 Type IIa

24

24 (22.9)

0 (0)

 

16 (21.6)

6 (21.4)

 

17 (23.9)

3 (25.0)

 

FIGO stage [cases (%)]b

   

0.012

  

0.266

  

0.354

 FIGO I

87

85 (81.0)

2 (33.3)

 

61 (82.4)

19 (67.9)

 

60 (84.5)

9 (75.0)

 

 FIGO III

19

15 (14.3)

4 (66.7)

 

11 (14.9)

8 (28.6)

 

8 (11.3)

3 (25.0)

 

 FIGO IV

4

4 (3.8)

0 (0)

 

2 (2.7)

1 (3.6)

 

3 (4.2)

0 (0)

 

 Unknown

1

1 (1.0)

0 (0)

 

0 (0)

0 (0)

 

0 (0)

0 (0)

 
  1. Italic values indicate significance of p value (p < 0.05)
  2. MMR: mismatch repair; IHC: immunohistochemistry; MSI: microsatellite instability; SD: standard deviation; BMI: body mass index; EC: endometrial carcinoma; FIGO: International Federation of Gynecology and Obstetrics
  3. aAmong 24 cases of type II endometrial cancer, there were nine cases of the serous subtype, three of clear cell carcinoma, four of carcinosarcoma, one of undifferentiated carcinoma, and seven cases of mixed carcinoma (four cases of endometrioid and clear cell carcinomas, two cases of the endometrioid and serous subtypes, and one case of endometrioid subtype and carcinosarcoma)
  4. bNo patients had FIGO II disease